Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with Radiation for Anal Canal Carcinoma
NCT01382745Phase 2Terminated
- Sponsor
- Dr. Te Vuong
- Start
- Jan 2012
- Primary completion
- Sep 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in anal canal squamous cell carcinoma (SCCA), sponsored by Dr. Te Vuong. Started Jan 2012; status: terminated.
02
Drugs
nimotuzumab
03
Conditions
anal canal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on NCT01382745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01382745.